Recent research Led by FDB Pharmacists and Health System Clinicians Increasing Shatters Age-Old Iodine Allergy Myths & Mythos, Added
SAN FRANCISCO, Calif., Sept. 15, 2021 First Databank, the leading medical device provider, published the research in an effort to refute the concept of iodine allergies, cited no
The findings were recently published in the magazine. American Journal of Health-System Pharmacy of the American Health Journal. The American Society of Health-System Pharmacists published this peer-reviewed journal. The radiologist who led the study was Nicole Wulf, PharmD, and Joan Kapusnik-Uner, the PhD in Rochester, Minn.; and her co-authors were John Schmitz,
The exhaustive investigation, seven years, critically examines the well-established, but often erroneous practice patterns of clinicians who fail to administer an iodine-containing contrast agent before taking a test to patients who A contrast agent or dye is a diagnostic aid that helps enhance the visibility of blood vessels and organ systems, and helps radiologists and other physicians identify abnormalities inside the body, such as tumors.
Dr. Wulf, the lead author and the FDB clinical pharmacist, said that the iodinated contrast media, amiodarone, povidone-iidine, and other ions containing compounds "While these patients likely had reactions to the contrast media, iodine is most likely not responsible, nor did most of these reactions meet the definition of an allergic reaction, which requires an immune-mediated reaction such as a release
As many patients as the general practice is, the iodine allergy is an allergy to shellfish or other seafood that contain a syringe. These self-reported, unverified "iodine allergies" could be based purely on the patient's perceived prior adverse reaction to a contrast agent, or dislike or intolerance to seafood, the latter of which
The patient can use contrast agents or iodine-containing medications to obtain the most appropriate imaging and care. According to the authors, high-risk medications with alerts at the point of ordering can help physicians and patients understand their risks, prompt further testing or an investigation into potential other causes of the allergic-type reaction.
A patient's iodine allergy is a non-respiratory consequence that can result in deterioration or if he isn't receiving an unnecessary steroids before an imaging test, is the co In the past, physicians and patients could determine the type of contrast media to which they had adverse reactions in the present and explore other ways to avoid those or similar ingredients formulations or if the reaction was actually due to another cause, such as
The research confirms the published guidelines for patients with self-reported iodine or shellfish allergies should receive contrast dye without premedicating the patient with steroids. The American Academy of Allergy, Asthma and Immunology states "the mechanism for anaphylaxis to radio-iodinated contrast media relates to the physiochemical properties of these media and is
Because of the growing volume of research, authors hope their study is a good way to encourage other medical societies and the U.S. Food and Drug Administration to adopt industry-wide changes to imaging protocols and prescribing guidelines. According to the authors, a clear consensus, improved clinical decision support at the point of ordering could help providers and patients experience fewer care delays, shorter hospital stays, less wasted imaging tests and overall improved patient outcomes.
Dr. Kapusnik-Uner points out that imaging studies using contrast media are very beneficial for physicians who manage diverse diseases, including cancer, heart disease, trauma, and many others. We research the idea that healthcare providers who still ask patients about iodine or seafood allergies should re-examine these protocols and implement a evidence-based safety screen. The bottom line is that contrast agents save lives and should be used when clinically indicated and safe to do so.
About FDB (First Databank) (Sale). FDB is the leading provider of medicines and medical devices that help healthcare professionals make precise decisions. We empower our information system developers partners serving the majority of hospitals, physicians, pharmacies, payers and all other healthcare industry segments to deliver valuable solutions that millions of clinicians each day, business associates or patients use. We have been using our drug knowledge for more than 40 years to improve patient safety, operational efficiency and healthcare outcomes. To complete our solutions and services, visit https://www.fdbhealth.com or follow us on Twitter, LinkedIn and
Hearst Health About Hearing Health. The mission of the mission is to a mission. Hearst health. To help guide the most important care moments by giving vital information to everyone who touches the health journey. In the United States each year, care guidance from Hearst Health reach 85 percent of discharged patients, 205 million insured individuals, 3,3 billion home health visits and 3,2 billion dispensed prescriptions. The Hearst Health Network includes the Heary Health network. FDBDBs. (First Databank), New York, April 19th, 2002. Health Zynx , a b. MCG , Homecare Homebase Homework Home base. and MHK (formerly MedHOK)). Hearst also is minor in the precision medicine and oncology analytics firm. M2Gen has a M2-Genesizer system. . Follow Hearst Health on Twitter. @HearstHealth @hearlsna. LinkedIn or Facebook @Hearst-Health @Thermosphere-Thema-Stooda .
First Databank, Inc. 2021 First databank part of the Hearst Health network.
Contact: Tara Stultz Amendola Communications for First Databank M: 440-225-9595 [email protected]. - : (440) 225-395 vs.
SOURCE First Databank.